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Abstract
Introduction: We evaluate the data of 12,644 Radical Cystectomies in England 
(Open, Robotic and Laparoscopic) with trends in the adaption of techniques and post- 
operative complications.
Methods: This analysis utilised national Hospital Episode Statistics (HES) from NHS 
England.
Results: There was a statistically significant increase (P < .001) in the number of 
Robotic assisted radical cystectomies from 10.8% in 2013- 2014 and 39.5% in 2018- 
2019.The average LOS reduced from 12.3 to 10.8 days for RARC from 2013 to 2019 
similarly the LOS reduced from 16.2 to 14.3 for ORC. The rate of sepsis (0- 90 days) 
did rise from 5% to 14.5% between 2013- 2014 and 2017- 2018 for the entire co-
hort (P < .001). Acute renal failure (ARF) increased over the years from 9.5% to 17% 
(P < .001). The rate for fever, UTI, critical care activity and ARF were higher for ORC 
than RARC (P < .001).The comparison of all episodes within 90 days for conduit ver-
sus non- conduit diversions showed significantly higher rates of sepsis, infections, UTI 
and fever in non- conduit group .Overall complications were significantly higher in 
non- conduit group throughout the duration except was year 2016- 17(P < .001).The 
robotic approach has increased in last 5 years with nearly 40% of the cystectomies 
now being robotically in 2018- 19 from the initial percentage of 10.8% in 2013- 14.
Conclusion: This evaluation of the HES data from NHS England for 12,644 RC con-
firms an increase in the adoption of Robotic Cystectomy. Our data confirms the 
need to develop strategies with enhanced recovery protocols and post- operative 
close monitoring following Radical Cystectomy in order to reduce post- operative 
complications.
K E Y W O R D S
bladder cancer, complications, cost, outcomes, radical cystectomy
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1  | INTRODUC TION
Open radical cystectomy (ORC) has evolved since its first description 
nearly 80 years ago.1 Perioperative outcomes have slowly improved, 
but overall, 90- day complication rates have been reported to be as 
high as 65%.2 Morbidity can particularly correlate with urinary diver-
sion technique.3 Robotic- assisted laparoscopic techniques were first 
used for RC in 2003.4 and the feasibility of Robot- Assisted Radical 
Cystectomy (RARC), has subsequently been demonstrated through 
randomized trials with potential advantages including reduced intra- 
operative blood loss and shortened hospital stay.5– 8 The RAZOR trial 
indicated oncological equivalence of robotic and open cystectomy 
with respect to two- year progression- free survival.9,10 The recently 
completed phase 3 iROC Trial which compared RARC with ORC will 
report length of stay as one of the primary outcome measures, pro-
viding further randomized data to inform comparisons.11
The robotic approach has received criticism due to cost impli-
cations and a lack of long- term oncological data; however, there 
is now a consistent increase in uptake of minimally invasive surgi-
cal approaches, especially in RARC over the last decade.12– 14 The 
European Association of Urology (EAU) in 2020 confirmed that 
RARC is a feasible and safe approach with comparable perioperative 
and long- term complications to ORC (level of evidence 1b).15– 18 The 
uptake of RARC in clinical practice worldwide has been thought to 
be slower than elsewhere in the developed world due to concerns 
about cost- efficiency.19,20 However, uptake of RARC in the United 
Kingdom is relatively unexplored in the scientific literature, nor has 
its impact upon shorter term outcomes been hitherto assessed.10
We sought to evaluate Hospital Episode Statistics (HES) data 
from 2013 to 2019 for all radical cystectomies (RC) performed in 
England, with a specific focus on trends in the surgical approach and 
implications on early outcomes, re- admissions, and interactions with 
the health care system within 90 days of surgery.
2  | METHODS
This analysis utilized national Hospital Episode Statistics (HES) 
data from NHS England, containing information on inpatient ad-
missions and outpatient appointments for all English NHS Clinical 
Commissioning Groups (CCGs)21 as reported at the time of patients’ 
interaction with the healthcare system. HES data were accessed 
using Harvey Walsh Health Informatics (Cheshire, UK) as a licensed 
intermediary. The work was supported by a research grant from 
Intuitive Surgical (California, USA). The data were pseudonymized 
at a source, precluding the need for ethical approval. Data are re-
corded on a real- time basis, avoiding any potential recall bias. Each 
“episode” is defined as an inpatient admission during which patients 
are assigned a diagnosis coded for in the International Statistical 
Classification of Diseases and Related Health Problems, 10th re-
vision (ICD- 10).22 The HES- recorded procedure- specific codes 
(Classification of Intervention and Procedure Codes or OPCS- 4) 
were used to identify patients from 2013 to 2019 and to classify 
each patient in to an operative group.23 The exact OPCS- 4 codes 
used are outlined in Annexure 1. Using this information patients 
were separated into three groups, namely ORC, Laparoscopic cys-
tectomy, and RARC. Patients were also stratified according to uri-
nary diversion technique, namely conduit or non- conduit diversion.
Patients who were either readmitted or attended an accident 
and emergency department in the first 90 days following their index 
procedure were also identified, along with the ICD- 10 diagnosis 
code corresponding to the reason for readmission. These data were 
available from years 2013- 2019 only.
For the cost analysis, data for the cost per procedure as well as 
the cost of re- admission per procedure were evaluated along with the 
global burden of expenditure in each modality for these past years.
2.1 | Statistical analysis
Data were descriptively analyzed. Continuous variables were de-
scribed using means and standard deviations and categorical varia-
bles were described using frequencies and percentages. A chi- square 
test for trend in proportions was used to test the null hypothesis that 
there was no trend in the proportions over years against the alter-
native hypothesis that there was a linear trend in the proportion of 
patients undergoing cystectomy. The Mann- Kendall test for trend 
was used to test the null hypothesis that there was no monotonic 
trend in the average length of stay (LOS) against the alternate hy-
pothesis that a trend does exist. Intergroup comparison for 90 days 
post- operative events in a particular year, along with entire duration, 
was performed with specific comparison between ORC and RARC 
cohorts. Intergroup analysis between different groups was per-
formed by chi- square test for trend in proportions. For cost analysis, 
the multivariate Mann- Kendall test, an extension of Mann- Kendall 
test for trend, was used to evaluate the global trend between the 
groups. For cost comparison pertaining to each specific complica-




From 2013 to 2019, HES data captured a total of 12,644 RC in 
England. Approximately 2,100 cystectomies were performed in each 
year. Overall, 9,056 patients were male (71.6%) and 3,588 (28.4%) 
were female. Only 1,118 (8.8%) patients were aged 50 years or under; 
692 patients (5.5%) were aged over 80 years at the time of surgery. 
The proportion of male: female patients was consistent across the 
time period (P = .185).. The age of patients increased over time, with 
the proportion of patients aged 70 and above increasing from 35.5% 
in 2013- 14 to 38.4% in 2018- 19 (P < .001). There was also a sig-
nificant decrease in the number of patients < 60 years undergoing 
cystectomy (P < .001). Within the entire cohort 38.6% of patients 
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had neo- adjuvant chemotherapy [36.6%— Laparoscopic Radical 
Cystectomy, 37.9%— Open Radical Cystectomy and 40.9%— Robotic 
Radical Cystectomy (P = .005)]. Demographic data and Baseline 
Characteristics (Table 1).
3.2 | Surgical approach
Across the cohort, 8,252 (65.3%) cystectomies were performed as 
ORC, 3,363 (26.6%) as RARC, and 1,029 (8.1%) as laparoscopic as-
sisted (LRC). There was a significant increase in the number of RC 
being performed robotically from 10.8% in 2013- 2014 to 40.2% in 
2018- 19 (P < .001) (Figure 1). A reduction in the rate of both LRC 
(P < .001) and ORC (P < .001) was noted during the same time 
period. The proportion of ORC procedures fell from 79.1% in 2013- 
14 to 54% in 2018- 19. The difference between the three approaches 
was significant both as a trend with respect to time and by inter-
group comparison within each year (Table 2).
3.3 | Length of stay
Mean LOS for the entire cohort was 12.5 days. Across all surgical 
approaches, there was a trend toward a decreased average length 
of spital stay (LOS) between 2013 and 2019 although this failed to 
reach statistical significance (Figure 2). The average LOS reduced 
from 12.3 to 10.8 days for RARC (P = .18) and from 16.2 to 14.3 days 
for ORC between the first and last time period, respectively.
TA B L E  1   Demographic data and baseline characteristics
Variable Level Overall LAP OPEN RAS P- value
n 12,644 1,029 8,252 3,363
Approach (%) LAP 1,029 (8.1)
OPEN 8,252 (65.3)
RAS 3,363 (26.6)
Gender (%) Male 9,056 (71.6) 684 (66.5) 5,754 (69.7) 2,618 (77.8) <.001
Female 3,588 (28.4) 345 (33.5) 2,498 (30.3) 745 (22.2)
IMD04 quartile (%) High 3,389 (27.3) 232 (22.7) 2,173 (26.9) 984 (29.8) <.001
Median 3,503 (28.2) 320 (31.3) 2,264 (28.0) 919 (27.8)
Low 3,007 (24.2) 263 (25.8) 1946 (24.1) 798 (24.2)
Very Low 2,504 (20.2) 206 (20.2) 1697 (21.0) 601 (18.2)
Year of operation (%) 2013/14 2,115 (16.7) 214 (20.8) 1673 (20.3) 228 ( 6.8) <.001
2014/15 2,102 (16.6) 210 (20.4) 1559 (18.9) 333 ( 9.9)
2015/16 2,100 (16.6) 165 (16.0) 1,448 (17.5) 487 (14.5)
2016/17 2068 (16.4) 142 (13.8) 1,236 (15.0) 690 (20.5)
2017/18 2093 (16.6) 172 (16.7) 1,167 (14.1) 754 (22.4)
2018/19 2,166 (17.1) 126 (12.2) 1,169 (14.2) 871 (25.9)
Age band (%) 0- 30 190 (1.5) 66 (6.4) 115 (1.4) 9 ( 0.3) <.001
31- 40 260 (2.1) 52 (5.1) 180 (2.2) 28 ( 0.8)
41- 50 668 (5.3) 58 (5.6) 471 (5.7) 139 ( 4.1)
51- 60 1816 (14.4) 125 (12.1) 1,208 (14.6) 483 (14.4)
61- 70 4,349 (34.4) 308 (29.9) 2,801 (33.9) 1,240 (36.9)
71- 80 4,669 (36.9) 364 (35.4) 3,003 (36.4) 1,302 (38.7)
81+ 692 ( 5.5) 56 ( 5.4) 474 ( 5.7) 162 ( 4.8)
Ethnic group (%) Asian 177 ( 1.4) 24 ( 2.3) 116 ( 1.4) 37 ( 1.1) <.001
Black 84 ( 0.7) 2 ( 0.2) 50 (0.6) 32 (1.0)
Other/Unknown 2,205 (17.4) 122 (11.9) 1,316 (15.9) 767 (22.8)
White 10,178 (80.5) 881 (85.6) 6,770 (82.0) 2,527 (75.1)
CCI index (%) 1 6,092 (48.2) 512 (49.8) 3,976 (48.2) 1604 (47.7) .001
2 2,213 (17.5) 142 (13.8) 1516 (18.4) 555 (16.5)
3 4,339 (34.3) 375 (36.4) 2,760 (33.4) 1,204 (35.8)
Prior chemotherapy (%) 4,882 (38.6) 377 (36.6) 3,130 (37.9) 1,375 (40.9) .005
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F I G U R E  1   Trend in radical cystectomy (RC) surgical approach over time
TA B L E  2   Trends in radical cystectomy (RC) surgical approach over time
Cystectomy procedure 
type
Percentage of patients by cystectomy type
Comparison with 
respect to time
2013/14 2014/15 2015/16 2016/17 2017/18 2018/19 P- value
RAS 228 (10.8%) 333 (15.8%) 487 (23.2%) 690 (33.4%) 754 (36%) 871 
(40.2%)
<.001
LAP 214 (10.1%) 210 (10%) 165 (7.9%) 142 (6.9%) 172 (8.2%) 126 (5.8%) <.001
Open 1673 (79.1%) 1559 (74.2%) 1,448 (69%) 1,236 (59.8%) 1,167 (55.8%) 1,169 (54%) <.001
Total procedures 2,115 2,102 2,100 2,068 2,093 2,166
Intergroup comparison <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
F I G U R E  2   Average length of stay following each surgical approach to cystectomy over time
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Following propensity- score matching, comparisons between 
RARC and ORC are shown in Table 2. Median LOS following RARC 
was 8 days for RARC, compared to 11 days for ORC (P < .001).
3.4 | Post- procedure events
Among all 12,644 patients, the proportion for whom there were 
recorded ICD codes for “post- operative events” within 90 days 
were consistently in the region of 90%. as well as for The rate of 
recorded sepsis rose from 5% to 14.5% (P < .001) (Table 2). The 
recorded acute renal failure/acute kidney injury (AKI) increased 
over time from 9.5% to 17% (P < .001). The proportion of pa-
tients listed for critical care activity and cardiac episodes also 
rose (P < .001). However, 90- day in- hospital mortality was stable 
across time periods (P = .270). A trend toward increasing rates of 
recorded sepsis, fever, and acute renal failure was seen across all 
surgical approaches (Table 3). Comparisons of 90- day events be-
tween RARC and ORC, following the propensity score matching, 
are outlined in Table 3.
The proportion of patients undergoing ORC that required critical 
care activity increased over time (P < .001) and had an increased rate 
of cardiac events (P < .007) (Table 3). Between surgical approaches, 
there was a consistently higher rate of infection and colostomy 
among patients undergoing open procedures compared to robotic 
or laparoscopic (P < .001).
Following propensity score matching, the rates of critical care ac-
tivity, were significantly lower for RARC patients, compared to ORC 
(P < .001), and were lower still for patients undergoing laparoscopic 
RC (P < .001) . Colostomy rates were 11.9% for ORC, compared to 
7.8% for RARC (P < .001).
When comparisons were made between those with conduit vs 
non- conduit diversions, significantly higher rates of sepsis, infec-
tions, UTI, and fever were seen in the non- conduit group. Overall 
complications were significantly higher in the non- conduit group 
throughout the time period (P < .001).
Table 3 Length of stay (LOS), readmission, LOS following read-
mission, and post- op events data comparisons for robotic- assisted 
cystectomy (RARC) compared to open cystectomy (ORC) following 
propensity score matching, across the whole data period.
3.5 | Readmissions
The overall rate of 90- day non- elective readmissions (NER) across 
our entire cohort was 25.9%. Overall there was a slow increase 
in NER over time from 23.9% to 28.2% (P < .001). NER for the 
RARC group fell over time (P < .001) but started at a relatively 
high rate of readmission of 37.7% in 2013- 14. Conversely, there 
was an increasing trend of NER following ORC, but the NER rate 
was low at the start of the time period (22.4%) NER for LRC was 
fairly low throughout, ranging between 13.7% and 27.3% in any 
year (Table 4). Following propensity score matching, the rate of 
90- day NER was significantly lower for LRC than either RARC or 
ORC (P = .015).
3.6 | Cost implications
The average cost per patient for RARC was £10,225 in the year 
2018/19 whereas the average cost per open cystectomy spell was 
£ 9,975 for the year 2018/19. The variation over these six years did 
not show any significant difference in either of the groups (P = .707 
and P = .450).] The intergroup comparison for the statistics for each 
year showed higher cost for RARC in comparison to ORC; how-
ever, global comparison for the trend did not show any significant 
variation (P .431). Average cost per patient per re- admission did not 
vary with the time for any of the approaches RARC (P = .707), LRC 
(P = .259), and ORC (P = 1.00). Nearly £2,500 was required to be 
spent on managing the NEL for ORC or RARC. The mean cost for 
managing sepsis within 1- 90 days showed a non- significant increas-
ing trend from 2013 to 2018 for all three groups (Table 4).
4  | DISCUSSION
This analysis of the HES data for six consecutive years from NHS 
England provides information on the trends in health care utilization 
for RC. The use of the robotic approach has increased over the past 
six years, with nearly 40% of cystectomies being performed roboti-
cally in 2018- 19 compared to 10.8% in 2013- 14. This large dataset of 
12,644 RC procedures may help to increase confidence in switching 
toward robotic- assisted or minimally invasive approaches in line with 
recent changes in international guidelines.17,24
Bladder cancer is the second most common urological cancer 
in the United Kingdom, with an estimated annual incidence rate of 
10,200 new cases every year.25 Mortality due to bladder cancer is 
high with 5,400 deaths annually in the United Kingdom, 3% of all can-
cer deaths. It is the seventh most common cause of cancer- related 
death in males.25,26 Significant debate surrounds the optimum sur-
gical approach in the management of bladder cancer, including de-
bates around the optimum outcome measures to use when assessing 
differences between approaches— which would include oncological, 
functional, and quality of life (QOL) related parameters.
The rate of uptake of RARC has increased globally; in the United 
States up to nearly one- quarter of cystectomies were performed 
robotically as early as 2013.13 Uptake in the NHS was slower ac-
cording to this dataset, perhaps due to a need for significant levels 
of published evidence on efficacy and cost viability to enable NHS 
funding. As highlighted in the clinical commissioning policy from NHS 
England, guidance did not support robot- assisted procedures for 
bladder cancer until July 2016.27 Though robot- assisted laparoscopic 
prostatectomy accounted for nearly 80% of UK prostatectomies in 
2016, surgeons performing RC appear to have been slower to have 
embraced a robotic approach (10,27) This analysis shows RARC is be-
coming more widely utilized in England.10 We demonstrate that length 
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TA B L E  3   Length of stay (LOS), readmission, LOS following readmission, and post- op events data comparisons for robotic- assisted cystectomy (RARC) compared to open cystectomy (ORC) 
following propensity score matching, across the whole data period
Overall LRC ORC RRC
P 
value
Index hospitalization LOS 
(median, IQR)
10.00 [7.00, 15.00] 9.00 [6.00, 13.00] 11.00 [8.00, 17.00] 8.00 [6.00, 12.00] <.001
90 day (non- elective) 
readmission (any diagnosis)
3,274 (25.9) 218 (21.2) 2078 (25.2) 978 (29.1) <.001
Average length of stay for 
readmission for cystectomy 
with a 90 day (NEL) 
readmission (any diagnosis) 
(median, IQR)
3.00 [1.00, 7.00] 2.00 [1.00, 6.75] 4.00 [1.00, 8.00] 3.00 [1.00, 7.00] .001
Other events (%) Patients (with any of the events listed) 11,490 (90.9) 809 (78.6) 7,627 (92.4) 3,054 (90.8) <.001
Sepsis 1,083 ( 8.6) 67 ( 6.5) 721 ( 8.7) 295 ( 8.8) .049
Other infections 1584 (12.5) 69 ( 6.7) 1,156 (14.0) 359 (10.7) <.001
Cardiac events 7,583 (60.0) 561 (54.5) 5,008 (60.7) 2014 (59.9) .001
Critical care activity 9,474 (74.9) 583 (56.7) 6,457 (78.2) 2,434 (72.4) <.001
Ventilation 570 ( 4.5) 36 ( 3.5) 422 ( 5.1) 112 ( 3.3) <.001
Acute renal failure 1797 (14.2) 137 (13.3) 1,149 (13.9) 511 (15.2) .142
Post Op complications 2,938 (23.2) 191 (18.6) 1962 (23.8) 785 (23.3) .001
Fever 429 ( 3.4) 26 ( 2.5) 300 ( 3.6) 103 ( 3.1) .084
UTI 1896 (15.0) 118 (11.5) 1,314 (15.9) 464 (13.8) <.001
Death (In Hospital) 321 ( 2.5) 20 ( 1.9) 225 ( 2.7) 76 ( 2.3) .157
Index hospitalization cost 










8,885.41 (3,883.99) 7,912.25 (4,120.34) 8,697.86 (4,163.33) 9,651.76 (2,822.10) <.001
30 day cost (median, IQR, 
mean, SD)









9,580.22 (4,879.01) 8,433.52 (4,991.19) 9,390.74 (5,264.42) 10,404.55 (3,550.68) <.001
90 day cost (median, IQR, 
mean, SD)









10,512.41 (5,813.69) 9,207.70 (5,885.50) 10,365.12 (6,186.41) 11,280.34 (4,616.07) <.001
Inpatient cost 90 day 
(median, IQR, mean, SD)









10,585.68 (5,768.67) 9,216.65 (5,881.35) 10,474.64 (6,128.47) 11,280.34 (4,616.07) <.001
Outpatient cost 90 day 
(median, IQR, mean, SD)
Inclusive of index hospitalization cost 104.59 [0.00, 244.90] 0.00 [0.00, 0.00] 104.59 [0.00, 256.71] NA [NA, NA] .293





















of stay (LOS) shows a declining trend across all surgical approaches, 
including following RARC, for which an average LOS of 10.8days was 
recorded in 2018- 19 which is comparable to the established litera-
ture.28 LOS following RARC was shorter than ORC. Other factors can 
influence and impact the length of stay in NHS practice such as social 
factors which may affect the ability to compare this data internation-
ally. LOS reductions across all surgical approaches may well be related 
to enhanced recovery protocols post- surgery, upon which there has 
been significant emphasis.. The apparently higher rates of colostomy, 
infection, LOS, and readmission in ORC may be related to more com-
plex cases or more advanced disease. Without data on tumor charac-
teristics, we cannot fully adjust for this here. However, we noted that 
comorbidity rates were similar in each surgery type.
Non- elective readmissions are a major factor in the cost effec-
tiveness of cystectomy approaches. We observed that the NER rate 
following RARC declined, and the rate following ORC increased over 
our study period. However, given their respective starting points, 
they converged toward a similar rate of around 25%. This may be due 
to the fact that RARC was in its early days of adoption in the United 
Kingdom in the initial years of data collection, whereas ORC was 
well- established. Alternatively, it may relate to changes in patient se-
lection over time. Similar comparisons in other datasets have shown 
no major difference between the surgical approaches in terms of 30- 
day readmission rates,13,29 although RC it is the authors’ opinion that 
readmission rates should be quoted until at least 90- days, as per our 
analysis. Of note, any in- person interactions between a patient and 
the health care system in the post- operative period will be reflected 
as NER in HES coding which may, for example, include attendances 
for catheter complications or stoma nurse clinic visits. It is reassuring 
that despite this potential over- estimation, overall 90- day NER rates 
in the United Kingdom are comparable to global data.
It is interesting to note the overall rate of recorded sepsis within 
90- days post cystectomy increased across our study period. This 
appears unlikely to be due to clinical reasons, but rather, may be an 
effect of increased awareness and reporting of the condition. The 
highest rate recorded was in 2015- 2016, corresponding with an NHS 
campaign in 2015 to detect and treat sepsis early.30 The American 
College of Surgeons National Surgical Quality Improvement Project 
database emphasizes that post RC, 25% of patients develop infec-
tions within 30 days with rates of sepsis being 12.7%.31 That study 
reported that operative time >480 minutes was associated with 
surgical site infections (SSI), sepsis, and UTI and that perioperative 
blood transfusion positively correlated with higher rates of SSI and 
sepsis.31 Indeed, it has been previously established that higher blood 
loss and the requirement of transfusions are more common in ORC 
than RARC, which was not further assessed in our work.9,17,28 Other 
work has shown that operative times may reduce over a surgeon's 
learning curve, or may be lower in high- volume centers which may 
help minimize the infection- risk post RC.31,32 Antibiotic strategies 
and levels of resistance may also play a role in this apparent increase 
in the infections reported by HES. Similarly, increased rates of AKI 
throughout the cohort may be related to changing awareness, and to 
evolving electronic blood reporting systems which may translate to 
increased coding of such conditions.
















Cystectomy with Urinary Diversion and 
Reconstruction with CC
389 £8,048 £9,272 3,492 £8,924 £9,947 1,074 £9,943 £10,108
Cystectomy with Urinary Diversion and 
Reconstruction without CC
220 £5,365 £7,346 1,265 £6,119 £7,420 395 £7,608 £7,774
Complex Open Bladder Procedures 
with CC Score 3+
79 £11,856 £11,097 580 £12,339 £11,103 814 £12,141 £11,440
Complex Open Bladder Procedures 
with CC Score 0- 2
42 £7,486 £7,361 286 £7,702 £7,381 641 £7,777 £7,629
Cystectomy with Urinary Diversion and 
Reconstruction, with CC Score 3+
69 £10,132 £9,763 787 £10,335 £9,895 66 £10,248 £9,796
Complex Open Bladder Procedures 
without Major CC
84 £6,467 £7,304 630 £6,223 £7,331 194 £7,180 £7,662
Cystectomy with Urinary Diversion and 
Reconstruction, with CC Score 0- 2
105 £7,588 £7,350 595 £7,166 £7,370 67 £7,637 £7,389
Complex Open Bladder Procedures 
with Major CC
29 £12,913 £11,719 300 £11,952 £11,834 70 £12,713 £12,272
Total Pelvic Exenteration 154 £15,326 £15,450
Urinary Diversion without Cystectomy 
with Malignancy
9 £8,087 £8,675 133 £7,733 £8,797
Complex Open, Upper or Lower 
Genital Tract Procedures
34 £8,507 £8,150
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Post- operative complications within 90- days remained relatively 
stable across the study period, and comparisons between ORC and 
RARC failed to demonstrate any difference (P = .599). Systematic 
reviews have reported that 90- day grade 3 complication rates favor 
RARC whereas high- grade complications are comparable between 
RARC and ORC.28 Other studies report in favor of RARC or equiv-
alence when compared to ORC taking in terms of complications, but 
randomized trial data reported equivalent results for this metric.9,33,34
Non- conduit diversions recorded significantly higher rates of 
sepsis, infections, UTI, fever, and complications compared to con-
duit diversions in our study, which is in keeping with published data 
(34). The data were limited in terms of comparing subgroups of di-
version techniques within each surgical approach. Longer operat-
ing time requirements, the need for catheters and stents and more 
anastomoses may be some of the reasons for higher infections in 
the non- conduit group. Another noteworthy detail from our study is 
the increasing number of older patients undergoing RC, with 38.4% 
of patients being > 70 years in 2018- 19. This may have implications 
on post- operative recovery, as well as altered susceptibility to infec-
tions in the post- operative phase.
Increasing uptake of RARC may have cost implications, which 
we have not explored thoroughly in this study. Published systematic 
review analyses have concluded RARC may be cost- effective com-
pared to ORC.35 Cost factors involved are predominantly based on 
equipment and operating room costs, length of stay, transfusion- 
related requirements, complications, and readmission- related expen-
diture.35 Effective ways to mitigate the potential higher cost of RARC 
may, therefore, be to reduce operative theater time, and increase 
the number of cases performed.35 Potential savings in RARC may be 
gained by the reduced burden on health care for readmissions.36 If 
the trend in reduced readmission rates following RARC continues, the 
cost- effectiveness analyses may move in favor of RARC. Additionally, 
the healthcare utilizations for managing sepsis, infections, UTI, fever, 
critical care activity, and acute renal failure, which stand significantly 
higher in ORC than RARC, may result in some downstream saving.37– 39
Particular strengths of this analysis relate to the large cohort 
size which represent real- world data from patients undergoing cys-
tectomy. HES data is objectively recorded by professional coders 
who are outside of surgical teams. This data is particularly useful 
for studying readmission data within a single nationalised health ser-
vice, which allows for broad comparison of trends.
We do, however, recognize potential limitations inherent to 
observational data, and to HES data specifically. HES data may be 
subjected to incorrect coding and overlapping terms such as UTI, 
infection, and sepsis resulting in skewed data. Accuracy of recording 
over time may not be consistent, and cannot be controlled for. This 
study was unable to assess functional and oncological outcomes, as 
no data are collected on this via the HES system, which could have 
helped contextualize metrics we have assessed such as LOS and re-
admission rate. Also, we were unable to report, or adjust for many 
patient or tumor characteristics. Propensity score- matching also has 
its limitations, particularly with regards to comparisons to the rela-
tively small laparoscopic cohort. Nonetheless, the large sample size 
helps counteract some of these limitations and allows broad com-
parisons to be made.
5  | CONCLUSION
This evaluation of NHS England HES data for 12,644 RC confirms 
a continued rise in the proportion of cystectomy being performed 
robotically. This paper emphasizes the need to further- develop en-
hanced recovery protocols and close post- operative monitoring of 
patients following radical cystectomy. RARC appears to have poten-
tial real- world benefits of reduced LOS and reduced rates of many 
90- day post- procedural events including infection, cardiac events, 
renal failure, and critical care activity.
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ANNE XURE 1 .
The HES recorded procedure- specific codes- Classification of 
Intervention and Procedure Codes (OPCS- 4) and International 
Statistical Classification of Diseases and Related Health Problems, 
10th revision (ICD- 10).
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